M3 Wake Research, Inc
Welcome,         Profile    Billing    Logout  
 9 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sood, Manu
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
NCT04759833 / 2022-003221-22: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
Cohen, Lisa
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Completed
3
97
US
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/25
03/25
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Recruiting
3
800
US
CHIKV VLP vaccine booster, PXVX0317, Placebo booster
Bavarian Nordic
Chikungunya Virus Infection
04/28
08/28
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
07/25
07/25
NCT04525976: A Phase I Study of the EmitBio™ RD19 Device to Prevent SARS-CoV-2 and COVID-19

Not yet recruiting
1
25
US
EmitBio™ RD19
KNOWBio Inc., M3-Wake Research Associates Carolina Phase I Clinical Trial Unit, TAB Clinical LLC
Respiratory Tract Infections
09/20
10/20
NCT04798001: Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Recruiting
1
130
US
Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Meissa Vaccines, Inc.
Covid19
10/22
10/22
NCT02454985: Group Medical Visits in Heart Failure for Post-Hospitalization Follow-Up

Not yet recruiting
N/A
375
US
HF-SMA, Heart Failure-Shared Medical Appointment
Providence VA Medical Center, Department of Veterans Affairs, Phoenix VA Health Care System
Heart Failure
05/18
12/19
OPTIMISTmain, NCT03734640 / ACTRN12619001556134: Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Completed
N/A
4922
Europe, US, RoW
Low-intensity monitoring strategy, Guideline recommended standard monitoring
Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia
Acute Ischemic Stroke Patients Receiving Reperfusion Therapy
12/24
01/25
Bhiwandi, Pouru
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting
4
1710
US
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Insud Pharma, Chemo Research
Change in Bone Mineral Density, Bone Loss
07/26
03/27
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
Pluto, Tiffany M
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Completed
3
97
US
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/25
03/25
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Active, not recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Knoop, Karol
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3)

Completed
3
218
Canada, US
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
08/24
08/24
Hong, Matthew
NCT05425719: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Completed
3
249
US, RoW
MB-102, Relmapirazin, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
MediBeacon
Chronic Kidney Disease
02/23
02/23
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
NA
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
02/24
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
Hira, Angela
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
07/25
07/25
Riley, Erika
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sood, Manu
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
NCT04759833 / 2022-003221-22: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
Cohen, Lisa
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Completed
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Completed
3
97
US
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/25
03/25
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Recruiting
3
800
US
CHIKV VLP vaccine booster, PXVX0317, Placebo booster
Bavarian Nordic
Chikungunya Virus Infection
04/28
08/28
SAP-001-202, NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Active, not recruiting
2
87
US
SAP-001, Xanthine Oxidase Inhibitor, Colchicine
Shanton Pharma Pte. Ltd.
Gout
01/25
02/25
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
07/25
07/25
NCT04525976: A Phase I Study of the EmitBio™ RD19 Device to Prevent SARS-CoV-2 and COVID-19

Not yet recruiting
1
25
US
EmitBio™ RD19
KNOWBio Inc., M3-Wake Research Associates Carolina Phase I Clinical Trial Unit, TAB Clinical LLC
Respiratory Tract Infections
09/20
10/20
NCT04798001: Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Recruiting
1
130
US
Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Meissa Vaccines, Inc.
Covid19
10/22
10/22
NCT02454985: Group Medical Visits in Heart Failure for Post-Hospitalization Follow-Up

Not yet recruiting
N/A
375
US
HF-SMA, Heart Failure-Shared Medical Appointment
Providence VA Medical Center, Department of Veterans Affairs, Phoenix VA Health Care System
Heart Failure
05/18
12/19
OPTIMISTmain, NCT03734640 / ACTRN12619001556134: Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Completed
N/A
4922
Europe, US, RoW
Low-intensity monitoring strategy, Guideline recommended standard monitoring
Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia
Acute Ischemic Stroke Patients Receiving Reperfusion Therapy
12/24
01/25
Bhiwandi, Pouru
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting
4
1710
US
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Insud Pharma, Chemo Research
Change in Bone Mineral Density, Bone Loss
07/26
03/27
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
Pluto, Tiffany M
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)

Completed
3
97
US
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/25
03/25
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Active, not recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Knoop, Karol
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3)

Completed
3
218
Canada, US
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
08/24
08/24
Hong, Matthew
NCT05425719: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Completed
3
249
US, RoW
MB-102, Relmapirazin, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
MediBeacon
Chronic Kidney Disease
02/23
02/23
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
NA
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
02/24
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
Hira, Angela
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Recruiting
3
180
US
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Ardelyx
Irritable Bowel Syndrome With Constipation (IBS-C)
12/25
12/25
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Recruiting
2
156
US
MHS-1031, Panosyl-isomaltooligosaccharide, Placebo
Microbiome Health Sciences, VBHRC Virginia Catalyst
Gastroesophageal Reflux
07/25
07/25
Riley, Erika
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23

Download Options